Navigation Links
PPTA Applauds Preserving Access to Orphan Drugs Acts
Date:6/14/2013

ANNAPOLIS, Md., June 14, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.

Representative Jim Gerlach (R-PA), introduced H.R. 2315 with lead cosponsor Rep. Richard Neal (D-MA), and Senator Patrick Toomey (R-PA), introduced an identical bill, S. 1128, with lead cosponsors Sens. Robert Casey (D-PA) and Mike Crapo (R-ID). "Representative Gerlach and Senator Toomey have demonstrated exceptional leadership and commitment to the rare disease community with this legislation," Julie Birkofer, PPTA Senior Vice President, North America said.

The budget neutral bills will clarify the orphan drug exclusion from the annual pharmaceutical fee by basing the exclusion on whether the therapy is solely approved for marketing by the Food and Drug Administration (FDA) to treat a rare disease or condition. Under current law, a product only is excluded from paying the annual fee if it has claimed the Orphan Drug Act tax credit. This has left many plasma protein therapies unable to qualify for the exclusion and disproportionately affects these lifesaving rare disease therapies. In the U.S., a rare disease or condition is generally defined as one affecting less than 200,000 persons.

"Claiming of the Orphan Drug Act tax credit is not the best way to define all rare disease therapies; many are left out of the exclusion despite treating orphan conditions," Birkofer said. "The optimal way to meet the needs of patients who rely on PPTs is to clarify the provision in the Affordable Care A
'/>"/>

SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CHPA Applauds Alabama Senates Passage of Anti-Meth Bill
2. CHPA Applauds Alabamas Adoption Of HB 363
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
6. Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
7. Novation Applauds FDAs Unique Device Identification Rule
8. American Academy of Pain Medicine Applauds FDA Action to Enhance Patient Safety on Prescribing Opioids; Offers AAPM Safe Opioid Prescribing Course as Educational Model
9. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
10. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
11. CRN Applauds Introduction Of Designer Anabolic Steroid Control Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... Talyst, a market leader in pharmacy automation, ... State Veterans Homes (NASVH) Summer Conference in ... NASVH is to ensure that each and every eligible ... care and respect which they have earned by their ... Remote Dispensing System, Talyst can help State Veterans Homes ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... 8, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., ... company that develops, manufactures and sells patented biopharmaceutical, ... pharmaceuticals, today announced that the senior management will ... quarter of fiscal year 2011 ending September 30, ...
... Md., Nov. 8, 2010 Substandard and counterfeit versions ... locations across Ghana by the Medicines Quality Monitoring surveillance ... Board (FDB) in collaboration with the U.S. Pharmacopeial Convention ... the program samples antimalarials across the public and private ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3
(Date:7/24/2014)... that involves direct oral suction is a likely source ... documented in infants between 1988 and 2012, a ... published online in the Journal of the Pediatric ... Penn,s Center for Evidence-based Practice , identified 30 ... The practiceknown as metzitzah b,pehand its link to HSV-1 ...
(Date:7/24/2014)... 2014 On October 24-25th, 2014, hundreds of ... the Embassy Suites LAX North for DiabetesSisters’ power-packed weekend conference. ... the first time it has convened Los Angeles, CA area. ... to open the entire event to both women with diabetes ... its kind worldwide for women with diabetes, the event offers ...
(Date:7/24/2014)... 24, 2014 (HealthDay News) -- A new formulation of ... snorting or injecting the drug has been approved by ... ER and made by Purdue Pharma, the pill is ... drug that blocks the euphoric effects of oxycodone. The ... snorted, dissolved or injected, according to the FDA. ...
(Date:7/24/2014)... CO (PRWEB) July 24, 2014 Skirt Sports, ... the 10-year anniversary of the running skirt. Born from an ... and debuted at an Ironman race in 2004, this one ... DeBoom used the prize money from her victory in Wisconsin ... line of run specific athletic skirts. , “When I drew ...
(Date:7/24/2014)... July 24, 2014 The North American Omega ... omega 3 & structured lipids market in North America with ... is estimated to grow from around $762.4 million in 2012 ... from 2013 to 2018. , Browse through the TOC of ... to get an idea of the in-depth analysis provided. This ...
Breaking Medicine News(10 mins):Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 5
... April 27 BioTrends is pleased to announce the ... SIMPONI (R) . Cenotcor ... for SIMPONI (R) (generic name: golimumab) ... anti-TNF-alpha therapy, SIMPONI is approved for the treatment of ...
... WASHINGTON, April 27 Speaker Nancy ... virus: "This afternoon, Majority Leader Hoyer and I were ... Obama Administration,s preparations to deal with the public health ... briefed us on the efforts that are being made ...
... 27 Speaker Nancy Pelosi released the following statement ... serve as Ambassador at Large and Global AIDS Coordinator:"President ... Ambassador at Large and Global AIDS Coordinator signals the ... Dr. Goosby is an excellent choice and is uniquely ...
... April 27 Young Innovations, Inc. (Nasdaq: YDNT ... 2009. Sales for the first quarter of 2009 were ... the $24.4 million reported in the first quarter of 2008. ... first quarter of 2009 from $4.6 million in the first ...
... BAX ), will host its annual shareholders meeting ... (10:30 a.m. Central Time)This call is being webcast by Thomson/CCBN ... http://www.baxter.com/ . The conference call ... It cannot be recorded or rebroadcast without Baxter,s permission.The webcast ...
... HSKA ) announces the following Webcast: (Logo: ... to Its Annual Meeting of Stockholders on the WebWhen: ... www.heska.com (click on the Annual Meeting of ... Live over the Internet -- Simply log on ...
Cached Medicine News:Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 5Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 6Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: